Medigene AG (MDG1) - Cash Flow Conversion Efficiency

Latest as of June 2024: -0.180x

Based on the latest financial reports, Medigene AG (MDG1) has a cash flow conversion efficiency ratio of -0.180x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.54 Million ≈ $-4.14 Million USD) by net assets (€19.66 Million ≈ $22.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Medigene AG net asset quality index to measure how much of total assets are equity-financed.

Medigene AG - Cash Flow Conversion Efficiency Trend (2006–2023)

This chart illustrates how Medigene AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Medigene AG cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Medigene AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medigene AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
CAP-EX IRON ORE
F:X0V
-0.025x
Biophytis S.A.
PA:ALBPS
0.472x
PALATIN TECHS DL-01
F:PTN
N/A
Chesterfield Resources PLC
LSE:CHF
-0.295x
WINDELN.DE SE INH O.N.
F:WDL1
N/A
Alliance Mining Corp
V:ALM
0.002x
Plantarc Bio Ltd
TA:PLNT
-0.235x
Jadestone Energy Inc
LSE:JSE
-0.014x

Annual Cash Flow Conversion Efficiency for Medigene AG (2006–2023)

The table below shows the annual cash flow conversion efficiency of Medigene AG from 2006 to 2023. For the full company profile with market capitalisation and key ratios, see Medigene AG (MDG1) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2023-12-31 €21.07 Million
≈ $24.63 Million
€-15.12 Million
≈ $-17.68 Million
-0.718x -321.90%
2022-12-31 €37.03 Million
≈ $43.29 Million
€11.98 Million
≈ $14.00 Million
0.323x +234.79%
2021-12-31 €44.82 Million
≈ $52.39 Million
€-10.75 Million
≈ $-12.57 Million
-0.240x +48.54%
2020-12-31 €53.15 Million
≈ $62.14 Million
€-24.79 Million
≈ $-28.98 Million
-0.466x -132.33%
2019-12-31 €81.82 Million
≈ $95.66 Million
€-16.42 Million
≈ $-19.20 Million
-0.201x -112.60%
2018-12-31 €107.42 Million
≈ $125.59 Million
€-10.14 Million
≈ $-11.86 Million
-0.094x +60.98%
2017-12-31 €86.17 Million
≈ $100.74 Million
€-20.85 Million
≈ $-24.37 Million
-0.242x -406.02%
2016-12-31 €78.59 Million
≈ $91.88 Million
€-3.76 Million
≈ $-4.39 Million
-0.048x +59.43%
2015-12-31 €89.99 Million
≈ $105.21 Million
€-10.61 Million
≈ $-12.40 Million
-0.118x +33.95%
2014-12-31 €49.07 Million
≈ $57.37 Million
€-8.76 Million
≈ $-10.24 Million
-0.178x +47.14%
2013-12-31 €36.28 Million
≈ $42.41 Million
€-12.25 Million
≈ $-14.32 Million
-0.338x -129.38%
2012-12-31 €44.22 Million
≈ $51.69 Million
€-6.51 Million
≈ $-7.61 Million
-0.147x -202.77%
2011-12-31 €47.93 Million
≈ $56.04 Million
€6.86 Million
≈ $8.02 Million
0.143x +151.20%
2010-12-31 €40.80 Million
≈ $47.70 Million
€-11.41 Million
≈ $-13.34 Million
-0.280x +23.34%
2009-12-31 €51.87 Million
≈ $60.64 Million
€-18.93 Million
≈ $-22.13 Million
-0.365x +13.45%
2008-12-31 €64.91 Million
≈ $75.88 Million
€-27.36 Million
≈ $-31.99 Million
-0.422x -35.63%
2007-12-31 €103.09 Million
≈ $120.53 Million
€-32.04 Million
≈ $-37.46 Million
-0.311x -2564.08%
2006-12-31 €108.51 Million
≈ $126.86 Million
€-1.27 Million
≈ $-1.48 Million
-0.012x --

About Medigene AG

XETRA:MDG1 Germany Biotechnology
Market Cap
$2.30 Million
€1.97 Million EUR
Market Cap Rank
#30008 Global
#2607 in Germany
Share Price
€0.13
Change (1 day)
+0.00%
52-Week Range
€0.13 - €0.13
All Time High
€36.05
About

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more